![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Fresenius Kabi |
---|---|
Information provided by: | Fresenius Kabi |
ClinicalTrials.gov Identifier: | NCT00860405 |
This study will compare the clinical efficacy and safety of Voluven® and Human Albumin during elective open-heart surgery in pediatric patients.
Condition | Intervention | Phase |
---|---|---|
Cardiac Surgery Cardiopulmonary Bypass |
Drug: HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L) Drug: Human serum albumin (HSA 50g/L) |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Efficacy and Safety of 6 % Hydroxyethyl Starch 130/0.4 (Voluven®) vs. 5% HSA in Volume Replacement Therapy During Elective Open-Heart Surgery in Paediatric Patients |
Estimated Enrollment: | 60 |
Study Start Date: | March 2009 |
Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Investigational drug: HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion)
|
Drug: HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L)
Study medication will be given as part of the priming of the ECC and for plasma volume replacement after start of ECC up to the maximum dosage of 50 mL/kg body weight/day.
|
2: Active Comparator
Control drug: Human serum albumin (HSA 50g/L
|
Drug: Human serum albumin (HSA 50g/L)
Human serum albumin (HSA 50g/L)
|
In the past, human albumin has been widely accepted as the therapeutic "gold standard" in paediatric volume replacement therapy because of the physiological hypoproteinemia in newborns and infants. In adult patients, artificial colloids such as hydroxyethyl starch have replaced human albumin as first choice in many settings. This study will compare the clinical efficacy and safety of HES 130/0.4 (6%) in normal saline vs. HSA 50g/L in volume replacement therapy during elective open-heart surgery in paediatric patients. The hypothesis of this study is to demonstrate that HES 130/0.4 (6%) and HSA 50g/L are equivalent regarding efficacy and provide comparable safety during elective open-heart surgery in paediatric patients 2 to 12 years of age.
Ages Eligible for Study: | 2 Years to 12 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Daniela Baus | +49-(0)6172 608 7324 | daniela.baus@Fresenius-Kabi.com |
Austria | |
AKh Allgemeines Krankenhaus der Stadt Linz GmbH | Recruiting |
Linz, Austria, 4021 | |
Contact: Hans Gombotz, Professor 0043-(0)732-7806-2158 hans.gombotz@akh.linz.at | |
Belgium | |
HUDERF - Hôpital Universitaire des Enfants Reine Fabiola | Not yet recruiting |
Brussels, Belgium, 1020 | |
Contact: Philippe Van der Linden, Professor 0032-(0)2-477-2330 philippe.vanderlinden@chu-brugmann.be |
Principal Investigator: | Philippe Van der Linden, Professor | HUDERF - Hôpital Universitaire des Enfants Reine Fabiola |
Principal Investigator: | Hans Gombotz, Professor | AKh Allgemeines Krankenhaus der Stadt Linz GmbH |
Responsible Party: | Fresenius Kabi Deutschland GmbH ( Daniela Baus , Clinical Project Manager ) |
Study ID Numbers: | HE06-001-C P4 |
Study First Received: | February 27, 2009 |
Last Updated: | April 28, 2009 |
ClinicalTrials.gov Identifier: | NCT00860405 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Hetastarch |